Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity

Diabetes and Metabolism

Volumn 24, Issue 4, 1998, Pages 355-361

  Luyckx, F H ^b   Scheen, A J ^b   Desaive, C ^b   Dewe, W ^b   Gielen, J E ^b   Lefebvre, P J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular risk factors; Gastroplasty; Obesity; Syndrome X; Weight loss

Indexed keywords

ADULT; ARTICLE; BODY WEIGHT; CORONARY RISK; FEMALE; GASTROPLASTY; HUMAN; INSULIN RESISTANCE; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORBID OBESITY; RETROSPECTIVE STUDY; RISK FACTOR; STAPLER; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; BELGIUM; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, HDL; COHORT STUDIES; COMORBIDITY; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; GASTROPLASTY; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; HYPERTRIGLYCERIDEMIA; INSULIN; INSULIN RESISTANCE; MALE; OBESITY, MORBID; PREVALENCE; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; URIC ACID; WEIGHT LOSS;

EID: 0031711816     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Sjöström L. Morbidity of severely obese subjects. Am J Clin Nutr, 1992, 55, 508S-515S.
2. Sjöström L. Mortality of severely obese subjects. Am J Clin Nutr, 1992, 55, 516S-523S.
3. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease : A 26-year follow-up of participants in the Framingham Heart Study. Circulation, 1983, 67, 968-977.
4. Jung RT. Obesity as a disease. Br Med Bull, 1997, 53, 307-321.
5. Chen Y-DI, Reaven GM. Insulin resistance and atherosclerosis. Diabetes Rev, 1997, 5, 331-342.
6. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Therapeutics, 1996, 18, 1006-1035.
7. Scheen AJ, Desaive C, Lefèbvre PJ. Therapy for obesity today and tomorrow. Baillière's Clin Endocrinol Metab, 1994, 8, 705-727.
8. Benotti P, Forse R. The role of gastric surgery in the multidisciplinary management of severe obesity. Am J Surg, 1995, 169, 361-366.
9. NIH Consensus Development Conference : Gastrointestinal surgery for severe obesity. Am J Clin Nutr, 1992, 55, 615S-619S.
10. Laws H. Standardized gastroplasty orifice. Am J Surg, 1981, 141, 393-394.
11. Kuzmak L. Gastric banding in surgery for the morbidly obese patient. In : Dietel M, ed. "Surgery for the morbidly obese patient", Chapter 12. Philadelphia : Lea and Febiger, 1989, 225-259.
12. Desaive C. A critical review of a personal series of 1000 gastroplasties. Int J Obesity, 1995, 19 (Suppl. 3), S61-S65.
13. SAS Institute Inc : SAS/STAT User's Guide, Version 6.11, Fourth edition. SAS Institute Inc. Cary, North Carolina, 1995.
14. Renquist KE, Cullen JJ, Barnes D, Tang S, Doherty C, Mason EE. The effect of follow-up on reporting success for obesity surgery. Obes Surg, 1995, 5, 285-292.
15. Kolanowski J. Surgical treatment for morbid obesity. Br Med Bull, 1997, 53, 433-445.
16. Scheen AJ, Paquot N, Letiexhe M, Paolisso G, Castillo MJ, Lefèbvre PJ. Glucose metabolism in obese subjects : lessons from OGTT, IVGTT, and clamp studies. Int J Obesity, 1995, 19 (Suppl. 3), S14-S20.
17. Van Gaal LF, Zhang A, Steijaert MM, De Leeuw IH. Human obesity : from lipid abnormalities to lipid oxidation. Int J Obesity, 1995, 19 (Suppl. 3), S21-S26.
18. Bonora E, Targher G, Zenere MB et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obesity, 1996, 20, 975-980.
19. Le Devehat C, Khodabandehlou T, Dougny M. Etudes des paramètres hémorhéologiques dans l'obésité isolée. Diabete Metab, 1992, 18, 43-47.
20. Valensi P, Paries J, Maheo P. Erythrocyte rheological changes in obese patients : influence of hypcrinsulinism. Int J Obesity, 1996, 20, 814-819.
21. Jarrett RJ. The cardiovascular risk associated with impaired glucose tolerance. Diab Med, 1996, 13, S15-S19.
22. Fontbonne A, Charles MA, Thibault N et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population : the Paris Prospective Population Study : 15-year follow-up. Diabetologia, 1991, 34, 356-361.
23. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary heart disease (the PROCAM experience). Am J Cardiol, 1992, 70, 733-737.
24. Gordon DJ, Probstfeld JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease : four prospective American series. Circulation, 1989, 79, 8-15.
25. Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and coronary heart disease risk : evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epid, 1995, 142, 288-294.
26. Ernst E. Fibrinogen : an independent risk factor for cardiovascular disease. BJM, 1991, 303, 596-597.
27. DeFronzo RA, Ferrannini E. Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and artherosclerotic cardiovascular disease. Diabetes Care, 1991, 14, 173-194.
28. Kolanowski J. Gastroplasty for morbid obesity : the internist's view. Int J Obesity, 995, 19 (Suppl. 3), S56-S60.
29. Toumiaire J, Fimbel S, Penet D et al. Traitement de l'obésité sévère par gastroplastie verticale calibrée : 55 observations. Presse Méd, 1995, 24, 259-262.
30. Leticxhc MR, Scheen AJ, Gérard PL, Desaive C, Lefèbvre PJ. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab, 1995, 80, 393-399.
31. Scheen AJ, Luyckx FH, Triches K, Letiexhe M, Desaive C, Lefèbvre PJ. Anomalies de la tolérance au glucose dans l'obésité sévère : réversibilité après amaigrissement induit par une gastroplastie. Rev Franç Endocrinol Clin, 1997, 38, 217-228.
32. Scheen AS. Aggressive weight reduction treatment in the management of type 2 diabetes. Diab Metab, 1998, 24, 116-123.
33. Datillo A, Kris-Etherton P. Effects of weight reduction on blood lipids and lipoproteins : a meta-analysis. Am J Clin Nutr, 1992, 56, 320-328.
34. Gleysteen JJ, Barboriak J, Sasse E. Sustained coronary-risk-factor reduction after gastric bypass for morbid obesity. Am J Clin Nutr, 1990, 51, 774-778.
35. Olsson S, Petersson B, Sörbris R, Nilsson-Ehle P. Effects of weight reduction after gastroplasty on glucose and lipid metabolism. Am J Clin Nutr, 1984, 40, 1273-1280.
36. Von Schenck, Wallentin L, Lennmarken C, Larsson J. Lipoprotein metabolism following gastroplasty in obese women. Scand J Clin Lab Invest, 1992, 52, 269-274.
37. Brolin R, Kenler H, Wilson A, Kuo P, Cody R. Serum lipids after gastric bypass surgery for morbid obesity. Int J Obesity, 1990, 14, 939-950.
38. Facchini F, Chen Y-DI, Hollenbeck CB. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA, 1991, 266, 3008-3011.
39. Ditschuneit H, Fleehtner-Mors M, Adler G. Fibrinogen in obesity before and after weight loss. Obes Res, 1995, 3, 43-48.
40. Luyckx FH, Desaive C, Thiry A et al. Liver abnormalities in severely obese subjects : effect of drastic weight loss after gastroplasty. Int J Obesity, 1998, 22, 222-226.
41. Sjöström L, Larsson B, Backman L et al. Swedish Obese Subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. Int J Obesity, 1992, 16, 465-479.
42. Sjöström L. Nabro K, Sjöström D. Costs and benefits when treating obesity. Int J Obesity, 1995, 19 (Suppl. 6), S9-S12.